United Therapeutics Corporation Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
United Therapeutics Corporation (UTHR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $97.50 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-22.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2023-02-22
- United Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $97.50M, a 266.54% increase from fiscal 2021.
- United Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $26.60M, a 16.16% increase from fiscal 2020.
- United Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $22.90M, a 99.13% increase from fiscal 2019.
- United Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2019 was $11.50M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2022-12-31 | $97.50M 10-K · filed 2023-02-22 |
| 2021-12-31 | $26.60M 10-K · filed 2023-02-22 |
| 2020-12-31 | $22.90M 10-K · filed 2023-02-22 |
| 2019-12-31 | $11.50M 10-K · filed 2022-02-24 |
| 2015-12-31 | $120.32M 10-K · filed 2016-02-25 |
| 2014-12-31 | $108.42M 10-K · filed 2016-02-25 |
| 2013-12-31 | $37.53M 10-K · filed 2016-02-25 |
| 2012-12-31 | $15.51M 10-K · filed 2015-02-24 |
| 2011-12-31 | $30.64M 10-K · filed 2014-02-25 |
| 2010-12-31 | $102.91M 10-K · filed 2013-02-26 |
| 2009-12-31 | $29.06M 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |